Have a feature idea you'd love to see implemented?
Let us know!
ENTA Enanta Pharmaceuticals Inc
Price (delayed)
$12.15
Market cap
$257.44M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.45
Enterprise value
$271.63M
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections
Highlights
The EPS has grown by 14% year-on-year and by 13% since the previous quarter
ENTA's net income is up by 13% year-on-year and by 12% since the previous quarter
The debt has soared by 83% YoY and by 8% from the previous quarter
The equity has decreased by 37% YoY and by 10% from the previous quarter
Key stats
What are the main financial stats of ENTA
Market
Valuations
Earnings
Shares outstanding
21.19M
Market cap
$257.44M
Enterprise value
$271.63M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.73
Price to sales (P/S)
3.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.77
Revenue
$71.96M
EBIT
-$106.61M
EBITDA
-$104.08M
Free cash flow
-$100.33M
Per share
Balance sheet
Liquidity
EPS
-$5.45
Free cash flow per share
-$4.74
Book value per share
$7.03
Revenue per share
$3.4
TBVPS
$18.83
Total assets
$398.82M
Total liabilities
$249.91M
Debt
$50.57M
Equity
$148.92M
Working capital
$228.35M
Debt to equity
0.34
Current ratio
4.92
Quick ratio
4.1
Net debt/EBITDA
-0.14
Margins
Efficiency
Dividend
EBITDA margin
-144.6%
Gross margin
100%
Net margin
-160.3%
Operating margin
-170.7%
Return on assets
-27.1%
Return on equity
-63.7%
Return on invested capital
-30.9%
Return on capital employed
-31.3%
Return on sales
-148.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ENTA stock price
How has the Enanta Pharmaceuticals stock price performed over time
Intraday
-4.71%
1 week
-1.06%
1 month
11.47%
1 year
35.3%
YTD
29.12%
QTD
17.28%
Financial performance
How have Enanta Pharmaceuticals's revenue and profit performed over time
Revenue
$71.96M
Gross profit
$71.96M
Operating income
-$122.87M
Net income
-$115.33M
Gross margin
100%
Net margin
-160.3%
ENTA's net income is up by 13% year-on-year and by 12% since the previous quarter
The gross profit has contracted by 11% YoY
Enanta Pharmaceuticals's revenue has decreased by 11% YoY
The net margin has grown by 11% from the previous quarter and by 2.2% YoY
Growth
What is Enanta Pharmaceuticals's growth rate over time
Valuation
What is Enanta Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.73
P/S
3.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.77
The EPS has grown by 14% year-on-year and by 13% since the previous quarter
The equity has decreased by 37% YoY and by 10% from the previous quarter
ENTA's P/B is 31% below its 5-year quarterly average of 2.5 but 15% above its last 4 quarters average of 1.5
The price to sales (P/S) is 59% lower than the 5-year quarterly average of 8.7
Enanta Pharmaceuticals's revenue has decreased by 11% YoY
Efficiency
How efficient is Enanta Pharmaceuticals business performance
Enanta Pharmaceuticals's return on equity has decreased by 36% YoY
ENTA's return on invested capital is up by 25% year-on-year and by 10% since the previous quarter
Enanta Pharmaceuticals's ROA has increased by 21% YoY and by 8% from the previous quarter
The return on sales has grown by 9% since the previous quarter and by 5% year-on-year
Dividends
What is ENTA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ENTA.
Financial health
How did Enanta Pharmaceuticals financials performed over time
The company's total assets is 60% higher than its total liabilities
Enanta Pharmaceuticals's quick ratio has decreased by 32% YoY and by 28% QoQ
Enanta Pharmaceuticals's current ratio has decreased by 25% YoY and by 23% from the previous quarter
The debt is 66% less than the equity
The company's debt to equity has surged by 183% YoY and by 21% QoQ
The debt has soared by 83% YoY and by 8% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.